AMAG Pharmaceuticals, Inc.  

(Public, NASDAQ:AMAG)   Watch this stock  
Find more results for Melissa Jordan�
0.00 (0.00%)
Jul 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 16.49 - 28.42
Open     -
Vol / Avg. 0.00/321,549.00
Mkt cap 405.21M
P/E     -
Div/yield     -
EPS -0.59
Shares 21.92M
Beta 0.00
Inst. own 116%
Jul 28, 2014
Q2 2014 AMAG Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
May 22, 2014
AMAG Pharmaceuticals, Inc. Annual Shareholder Meeting
Apr 24, 2014
Q1 2014 AMAG Pharmaceuticals, Inc. Earnings Release
Apr 24, 2014
Q1 2014 AMAG Pharmaceuticals, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -34.09% -11.88%
Operating margin -28.75% -14.37%
EBITD margin - -9.22%
Return on average assets -8.00% -3.67%
Return on average equity -15.67% -5.56%
Employees 148 -
CDP Score - -


1100 Winter Street
United States - Map
+1-617-4983300 (Phone)
+1-617-4993361 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


AMAG Pharmaceuticals, Inc. is a specialty pharmaceutical company that markets Feraheme (ferumoxytol) Injection for Intravenous (IV), used to treat iron deficiency anemia (IDA), in adult patients with chronic kidney disease (CKD), and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucositis. The Company sells Feraheme to authorized wholesalers and specialty distributors, who in turns, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers, and nephrology clinics. Its principal source of revenue is from the sale of Feraheme (ferumoxytol) Injection for intravenous (IV). It markets and sells Feraheme in both the dialysis and non-dialysis CKD markets, including to nephrologists, hematologists, dialysis organizations, hospitals and other end-users who treat patients with CKD.

Officers and directors

Gino Santini Chairman of the Board
Age: 57
Bio & Compensation  - Reuters
William K. Heiden President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Frank E. Thomas Chief Operating Officer, Executive Vice President
Age: 44
Bio & Compensation  - Reuters
Scott A. Holmes Senior Vice President - Finance and Investor Relations, Chief Accounting Officer, Treasurer
Age: 39
Bio & Compensation  - Reuters
Scott B. Townsend Senior Vice President - Legal Affairs, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Edward Jordan Senior Vice President - Sales and Marketing
Age: 46
Bio & Compensation  - Reuters
Steven Caffe M.D. Senior Vice President, Chief Development and Regulatory Officer
Age: 54
Bio & Compensation  - Reuters
Melissa Bradford Klug Senior Vice President - Business Development and Strategy
Bio & Compensation  - Reuters
Christopher G. White Chief Business Officer, Senior Vice President
Bio & Compensation  - Reuters
Lesley Russell Cooper Independent Director
Age: 53
Bio & Compensation  - Reuters